Next Article in Journal
Lynch Syndrome: From Carcinogenesis to Prevention Interventions
Next Article in Special Issue
Circulating Long Non-Coding RNAs Could Be the Potential Prognostic Biomarker for Liquid Biopsy for the Clinical Management of Oral Squamous Cell Carcinoma
Previous Article in Journal
Immunization Combined with Ferroptosis Related Genes to Construct a New Prognostic Model for Head and Neck Squamous Cell Carcinoma
Previous Article in Special Issue
Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 17
10.3390/cancers14174101
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast Cancer

Cancers 2022, 14(17), 4101; https://doi.org/10.3390/cancers14174101
by Henrike Herzog 1, Senol Dogan 2, Bahriye Aktas 1 and Ivonne Nel 1,*
Reviewer 1: Anonymous
Cancers 2022, 14(17), 4101; https://doi.org/10.3390/cancers14174101
Submission received: 6 July 2022 / Revised: 19 August 2022 / Accepted: 22 August 2022 / Published: 24 August 2022
(This article belongs to the Special Issue Promising Biomarkers in Liquid Biopsy of Cancer)

Round 1

Reviewer 1 Report

Herzog et al. analyzed plasma-derived and matching urinary cfDNA samples obtained from 15 presurgical triple negative breast cancer patients. The results showed the difference of somatic breast-cancer related variants in plasma-derived and urinary cfDNA. And their results indicated that body fluids may be valuable sources bearing complementary information regarding the genetic tumor profile. The topic is interesting, and there are some comments to the authors.

Comments:

1.       What are the main factors affecting cfDNA concentrations? The author needs to discuss them in the discussion section.

2.       The results showed that a total number of 431 was found in the ctDNA of both body fluids. Which tissues do these ctDNA mainly originate from? What evidence is there to support it. Which signaling pathways are these altered genes mainly enriched in?

3.       MUC16 and KMT2C are the most altered genes in both ctDNA sources. Whether these results are consistent with the genetic changes in TNBC patient tissues needs to be discussed.

4.       Utility of plasma and urinary ctDNA to monitor the breast cancer is still a huge challenge. Which of blood ctDNA or urine ctDNA is more suitable for early diagnosis of TNBC? Please discuss in depth in the discussion section.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

 

Henrike Herzog et al., investigated Targeted sequencing of plasma-derived vs. urinary cfDNA 2

from patients with triple negative breast cancer   The study is well-performed and the discussion is well-organized and comprehensive. Nevertheless, there are certain factors that must be fixed before publication:

 

1- Aim of the work should be stated clearly in introduction

            2- The purity of starting materials which used in the investigation should be added

3-How DNA is kept? Targeted sequencing of plasma-derived vs. urinary cfDNA 2

from patients with triple negative breast cancer

4- Comparison with related studies are is  recommended

        8-Finally, Please review English grammar before publication.

 

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

The authors have been replied the reviewer's comments point to point. And the revised manuscript was improved.

Back to TopTop